New drug tested to protect transplanted livers
NCT ID NCT06455280
Summary
This early-stage study is testing the safety of an investigational drug called siplizumab in patients with autoimmune liver disease who are receiving a liver transplant. The drug is given right after surgery to help prevent the body's immune system from attacking the new liver. Up to 8 participants will receive two doses of the drug and be followed for one year to monitor for side effects and see how well the transplanted liver is accepted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.